Hemant Surgical Reports Strong Growth and Major Tender Wins

Profit after tax (PAT) reached Rs 18.23 crore; Total income surged to Rs 236.71 crore.

Reader Takeaway: Robust financial growth and a massive Rs 350 crore order win highlight strong operational momentum for Hemant Surgical.

What just happened

Hemant Surgical Industries Limited has declared its financial results for FY 2025-26, showing a significant jump in profitability and revenue. The company’s profit after tax rose to Rs 18.23 crore from Rs 8.13 crore in the previous year. Total income grew to Rs 236.71 crore, up from Rs 111.50 crore in FY25. The company also announced the acquisition of a 66.66% stake in Lifesenz Cancer Research Labs.

Why this matters

The company secured a major CMSS tender worth approximately Rs 350 crore for the supply of handheld X-ray machines and flat panel detector systems. This order provides strong revenue visibility for upcoming quarters. Additionally, the company is shifting toward full localization of products like JMS MediTape, which is expected to lower import costs and improve margins.

Strategic Developments

Hemant Surgical is actively expanding its footprint with a new 100,000 sq ft manufacturing facility in Shambhaji Nagar, Maharashtra. The company is also collaborating with international partners Rayence (Korea) and Zoncare (China) to manufacture digital radiology and ultrasound equipment in India, with commercial production slated for January 2027 at the Atgaon facility.

AGM Notice

The 37th Annual General Meeting is scheduled for September 29, 2026, at 12:30 P.M. via video conferencing. The agenda includes the adoption of financial statements and the re-appointment of Mr. Hemant Praful Shah as a Whole-Time Director.

What to track next

Investors should monitor the scaling of the Shambhaji Nagar facility and the successful execution of the Rs 350 crore CMSS order. Further updates on the commercial production timeline for the radiology and ultrasound product lines will be key to long-term valuation.